Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (10386)	1/27/2003 5:28:23 PM
From: tsigprofit	Respond to of 48461

>> Question? Will this be good for the biorats we know and love? If so, which ones? William, I did some research, and found some names, but I don't really like any of the ones I saw at current prices! Found this link - but again, I don't see buying any of these right now: trendmacro.com Maybe this guy will update his site over time with more names and ideas. matt

To: Bucky Katt who wrote (10386)	1/27/2003 7:10:07 PM
From: RockyBalboa	Read Replies (2) \| Respond to of 48461

Hmm, tough call. After the war begins, those bio rat types might fall out when all is perhaps jumping back into non-defense securities, tech stock etc..... But as you ask, some bio rats from last year, or recent spikes come to my mind: CPHD, SIGA, AVAN, hmm, well, AATK (but that one lets all others appear like blue chips - I was short AATK last year after its spike). AATK jumped today quite a bit. Recently, AVAN had some news about an "anthrax vaccine contract", perhaps they put out more news, who knows. It undid its recent spike but didn't drop much since.

To: Bucky Katt who wrote (10386)	1/28/2003 10:58:43 AM
From: xcr600	Read Replies (4) \| Respond to of 48461

How's the response been in Chicago? 3 HealthEast hospitals opt out of smallpox vaccination program Dane Smith Star Tribune Published Jan. 26, 2003 Three hospitals in the HealthEast system are the latest to opt out of the federal government's voluntary smallpox vaccination program for doctors, nurses and other health care workers. HealthEast officials have decided not to immunize health care workers, at least in Phase I of the program, because of concerns from the workers about potential health threats from the vaccinations, said Anne Sonnee, spokeswoman for the hospitals. Hospitals affected by the decision are St. Joseph's in St. Paul, St. John's in Maplewood and Woodwinds in Woodbury. The smallpox vaccination program was initiated because of fears that terrorists might somehow acquire and spread the smallpox virus. Federal officials want to vaccinate enough health care professionals to care for victims if an outbreak occurs. In its first phase, the vaccine will be available for a small number of key doctors and nurses who would be designated as the first responders to an outbreak. In its second phase, the vaccine will be ready for a larger group of health care workers. However, the vaccinations, for a disease long ago considered eradicated, carry some risks of serious side effects, especially for people with certain health conditions, such as eczema or other skin problems. The number of workers who have volunteered to receive the vaccine is smaller than state Health Department officials had expected, but state officials say that enough hospitals and workers are participating to provide an adequate response to an outbreak.

To: Bucky Katt who wrote (10386)	1/28/2003 12:55:58 PM
From: CusterInvestor	Read Replies (2) \| Respond to of 48461

ANLX may be a candidate: Release: Contact: IMMEDIATE Amber Gordon Sterling Phillips (703) 329-9400 For: ANALEX CORPORATION (Symbol: ANLX) ANALEX'S ADVANCED BIOSYSTEMS SUBSIDIARY AWARDED NEW $3 MILLION BIODEFENSE CONTRACT BY DARPA Alexandria, VA, August 1, 2002 - Analex Corporation (OTC BB: ANLX) today announced that its Advanced Biosystems, Inc. subsidiary has been awarded a new $3 million contract by the Defense Advanced Research Projects Agency (DARPA). This eight-month contract builds upon medical biodefense research findings previously funded by DARPA, and initiates studies to develop immune system research models. Other members of Advanced Biosystems' team include George Mason University, Sciperio, Inc., Southern Research Institute, and Structural Bioinformatics, Inc. The research is being conducted under the direction of Advanced Biosystems' Vice Chairman and Chief Scientist, Dr. Ken Alibek, who has vast experience in the development of these and other novel methods of prophylaxis (prevention) and treatment of a broad spectrum of infectious diseases. This new biodefense contract focuses on researching ways to enhance the body's innate immune response against a wide variety of biological weapons threats. The areas under investigation will include an expansion of prior in vitro and in vivo studies of the effects of certain cytokines and other modulators of the innate immune response; the computer modeling, design, construction, and in vitro testing of a new peptide designed to mimic the immunomodulating effects of a specific cytokine; and initial studies of various tissue deposition techniques to be used in creating a three-dimensional model of mucosal immunity. "We are gratified that our prior research has yielded promising results, and we are pleased to continue working with DARPA to develop advanced protection against biological threat agents," Dr. Alibek stated. "Under this contract we will also continue the development, and small animal in vivo testing, of prototype biodefense products. Our Company continues to explore opportunities to license its developing technology to, or seek a joint venture with, a partner to complete the necessary clinical trials, regulatory approvals, and the development, manufacturing, and marketing of any future products that might arise from this work," he added. Analex's President and Chief Executive Officer, Sterling Phillips, commented, "We are pleased with the continuing recognition of Advanced Biosystems' efforts to develop protection against biological agents that may be used in warfare or terrorist attacks. This research is an important component of Analex's commitment to supporting national security." ANALEX specializes in developing intelligence, systems engineering and biodefense solutions in support of our nation's security. Analex focuses on designing, developing and testing aerospace products and systems; developing innovative technical solutions for the intelligence community, analyzing and supporting defense systems; and developing medical defenses and treatments for infectious agents used in biological warfare and terrorism. The Company's stock trades on the OTC Electronic Bulletin Board under the symbol ANLX. The Company can be found on the Internet at www.analex.com. Analex investor relations can be contacted at (703) 329-9400 or via email at agordon@hadron.com.